Vinblastine, intermittent bleomycin, and single-dose cis-dichlorodiammineplatinum(II) in the management of stge III testicular cancer.
A program for treating advanced testicular cancer with vinblastine, bleomycin, and a single dose of cis-dichlorodiammineplatinum(II) was used in an attempt to reduce the toxicity of a 5-day regimen while maintaining a high response rate. In ten previously untreated and six previously treated patients, the complete remission rate was 25%. Toxic reactions were frequent, and there was one drug-related death. This single-dose cis-dichlorodiammineplatinum(II) program is ineffective in the treatment of testicular cancer. Other means for reducing toxicity will have to be considered.
D000293:Adolescent; D000328:Adult; D001761:Bleomycin / Q000008:administration & dosage* / Q000009:adverse effects; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects; D004359:Drug Therapy, Combination; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D013736:Testicular Neoplasms / Q000188:drug therapy* / Q000473:pathology; D013921:Thrombocytopenia / Q000139:chemically induced; D014747:Vinblastine / Q000008:administration & dosage* / Q000009:adverse effects
D001761:Bleomycin; D014747:Vinblastine; D002945:Cisplatin